Reference health
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
30827-7/badge.svg){kind=icon}
17/17 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 17 checked references that resolve
resolves10.3322/caac.21492
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
resolves10.1093/annonc/mdw235
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
resolves10.1016/j.ctrv.2014.02.006
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/− targeted therapy
resolves10.1016/S1470-2045(12)70345-5
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
resolves10.1056/NEJMoa1414325
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
resolves10.1200/JCO.2017.74.3245
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
resolves10.1016/S0140-6736(12)61900-X
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
resolves10.1016/S1470-2045(15)70156-7
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
resolves10.1080/0284186X.2019.1605192
A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer
resolves10.2217/fon-2018-0147
Trifluridine/Tipiracil: An Emerging Strategy for the Management of Gastrointestinal Cancers
resolves10.1016/j.ejca.2017.10.009
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
resolves10.1136/esmoopen-2017-000261
Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial
resolves10.1016/S1470-2045(17)30425-4
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study
resolves10.1016/S1470-2045(13)70154-2
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
resolves10.1016/S0140-6736(14)62004-3
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
resolves10.1016/j.ejca.2018.10.009
Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis
resolves10.1016/j.jgo.2015.07.002
Chemotherapy in the oldest old: The feasibility of delivering cytotoxic therapy to patients 80years old and older
The 3 references without a DOI — listed, not checked
no DOI — not checkedEfficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
no DOI — not checkedThe role of angiogenesis inhibitors re-challenge in colorectal cancer previously treated with bevacizumab: a meta-analysis of randomized controlled trials
no DOI — not checkedPhase II study evaluating trifluridine/tipiracil+bevacizumab and capecitabine+bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/s1470-2045(19)30827-7"><img src="https://citestamp.com/citestamped/10.1016/s1470-2045(19)30827-7/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[30827-7/badge.svg)](https://citestamp.com/citestamped/10.1016/s1470-2045(19)30827-7)